

**REMARKS**

Entry of the foregoing amendments prior to examination is respectfully requested.

Respectfully submitted,

By

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

卷之三

## **VERSIONS WITH MARKINGS TO SHOW CHANGES MADE**

4. (Amended) A purified polynucleotide sequence encoding a [protein or fragment] nuclear matrix protein that is present in normal renal cells but absent in cancerous renal cells, or that is absent in normal renal cells but present in cancerous renal cells, or a fragment thereof.

15. (Amended) An antibody which binds to the protein encoded by the nucleotide sequence of claim [1] 4.

18. (Amended) A method for detecting a cell proliferative disorder in a subject, comprising contacting a cellular component from the subject with a reagent which binds to a cellular component associated with a cell proliferative disorder,

[The method of claim 17] wherein the cellular component is nucleic acid.

22. (Amended) The method of claim [16] 18, wherein the reagent is a probe.

35. (Amended) A method of gene therapy, comprising introducing into the cells of a host subject an expression vector comprising [a] the nucleotide sequence [encoding a protein] of claim [1] 4.

44. (Amended) A kit useful for the detection of a cell-proliferative disorder [associated with a protein of claim 1], said kit comprising a probe for identifying [a protein or fragment of claim 1 or a] the polynucleotide sequence [encoding a protein or fragment] of claim [1] 4.

□ □ □ □ □ □ □ □ □ □ □ □